

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

patent

Neumann 1



Identifying Informa	ition				
1. Given Name (First Name) Peter	2. Surname (Last Nar Neumann	me)		3. Date 27-October-2016	
4. Are you the corresponding author?	✓ Yes No				
5. Manuscript Title Cost-Effectiveness Analysis 2.0					
6. Manuscript Identifying Number (if you kno 16-12619	w it)				
Section 2. The Work Under Co	nsideration for P	ublication			
Did you or your institution <b>at any time</b> received any aspect of the submitted work (including be statistical analysis, etc.)?  Are there any relevant conflicts of interest	out not limited to grar				c.) for
Section 3. Relevant financial a	ctivities outside	the submitted	work.		
Place a check in the appropriate boxes in of compensation) with entities as described clicking the "Add +" box. You should report the entities and relevant conflicts of interest the entitle of the enti	ed in the instruction or relationships that:  Yes	ns. Use one line fo	or each en	tity; add as many lines as you need	d by
If yes, please fill out the appropriate infor	mation below.				
Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments	
Merck, Bayer, Pacira, Novo Nordisk, Shire, Amgen				Have served one-time advisory boards on health economics topics	
Congressional Budget Office			<b>✓</b>	Advisory board	
Boston Health Economics, Vertex, Precision Health Economics			$\checkmark$	Consulted	
The CEA Registry Sponsors			<b>✓</b>	The CEA Registry has been funded by NSF, NLM, AHRQ, CDC, and a variety of pharmaceutical and device companies who subscribe to the data.	

Neumann 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Neumann reports other from Merck, Bayer, Pacira, Novo Nordisk, Shire, Amgen, other from Congressional Budget Office, other from Boston Health Economics, Vertex, Precision Health Economics, other from The CEA Registry Sponsors, outside the submitted work; .

## **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Neumann 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1. Identifying Ir	formation			
Given Name (First Name)  Joshua	2. Surname (Last Name) Cohen		3. Date 17-July-2017	
4. Are you the corresponding author	? ✓ Yes No			
5. Manuscript Title A call for open source cost-effecti	veness analysis			
6. Manuscript Identifying Number (if M17-1153	you know it)			
Section 2. The Work Und	der Consideration for Pub	lication		
Did you or your institution <b>at any tim</b> any aspect of the submitted work (inc statistical analysis, etc.)?  Are there any relevant conflicts of	luding but not limited to grants, o			
If yes, please fill out the appropria Excess rows can be removed by p	te information below. If you ha	ave more than one enti	ty press the "ADD" button to ad	d a row.
Name of Institution/Company	Grant'	on-Financial Other?	Comments	
Bill and Melinda Gates Foundation	<b>✓</b>		Investment ID OPP1171680	
National Institutes of Health	✓		NIH Grant Award Number: U01NS086294	
Section 3. Relevant final	ncial activities outside the	submitted work.		
Place a check in the appropriate b of compensation) with entities as clicking the "Add +" box. You show Are there any relevant conflicts of If yes, please fill out the appropria	described in the instructions. I ald report relationships that w interest?  Yes  No	Use one line for each er	ntity; add as many lines as you n	eed by
Name of Entity	Grant	on-Financial Other?	Comments	
National Pharmaceuticals Council	<b>✓</b>			
Pharmaceutical Research Manufacturers America	of 🗸			



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Amgen	<b>✓</b>					
Biogen	<b>✓</b>					
GE Healthcare	<b>✓</b>					
Genentech	<b>✓</b>					
Gilead	<b>✓</b>					
Janssen	<b>✓</b>					
Lundbeck		$\checkmark$				
Merck	<b>✓</b>					
Novartis	<b>✓</b>					
Otsuka	<b>✓</b>					
Pfizer	<b>✓</b>					
Precision Health Economics		$\checkmark$				
Purdue Pharma	<b>✓</b>					
Sanofi	<b>✓</b>					
Vertex	<b>✓</b>					
Section 4. Intellectual Property Patents & Copyrights  Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo						
Section 5. Relationships not covered above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below):  No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, jo On occasion, journals may ask authors to						ients.



### Section 6.

### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Cohen reports grants from Bill and Melinda Gates Foundation, grants from National Institutes of Health, during the conduct of the study; grants from National Pharmaceuticals Council, grants from Pharmaceutical Research Manufacturers of America, grants from Amgen, grants from Biogen, grants from GE Healthcare, grants from Genentech, grants from Gilead, grants from Janssen, personal fees from Lundbeck, grants from Merck, grants from Novartis, grants from Otsuka, grants from Pfizer, personal fees from Precision Health Economics, grants from Purdue Pharma, grants from Sanofi, grants from Vertex, outside the submitted work.

### **Evaluation and Feedback**

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	ation					
1. Given Name (Fir	rst Name)	2. Surnai Wong	ne (Last Nar	ne)		3. Date 19-July-2017	
4. Are you the cor	responding author?	Yes	<b>✓</b> No	Correspond Joshua Co	•	or's Name	
5. Manuscript Title A call for open so	e ource cost-effectiveness	analysis					
6. Manuscript Ider M17-1153	ntifying Number (if you kno	ow it)					
Section 2.	The Work Under Co	nsidera	tion for P	ublication			
any aspect of the s statistical analysis, Are there any rele	ubmitted work (including etc.)? evant conflicts of intere	but not lin	nited to gran	its, data monitoring	board, stu	ent, commercial, private foundation, etc.) for udy design, manuscript preparation, ty press the "ADD" button to add a row.	
	pe removed by pressing						
Name of Institut	ion/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Agency for Healthcar	e Research Quality	<b>✓</b>				Methods Research Report funded by AHRQ contract number HHSA 290 2007 10055 I	•
National Institutes of	Health	<b>✓</b>				NIH Grant Award Number: U01NS086294	
Section 3.	Relevant financial a	ctivities	outside 1	the submitted	work.		
of compensation clicking the "Add Are there any rele	) with entities as describ	oed in the ort relationst?	instruction onships tha Yes	ns. Use one line fo	or each er	ial relationships (regardless of amount atity; add as many lines as you need by a 36 months prior to publication.	
Name of Entity		Grant?	Personal Fees	Non-Financial Support?	Other?	Comments	
American College of I	Physicians		<b>√</b>			Associate Statistical Editor for the	•



Name of Entity	Grant?	Personal Fees	Non-Financial Support?	Other?	Comments		
Cambridge Press		<b>✓</b>			Royalties for Decision Making in Health and Medicine		
Wolters Kluwer		<b>✓</b>			Royalties for Learning Clinical Reasoning		
Section 4. Intellectual Propert	y Pate	ents & Cop	oyrights				
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes V		
Section 5. Relationships not c	overed	above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
Yes, the following relationships/cond	itions/cir	cumstance	s are present (exp	olain belo	ow):		
No other relationships/conditions/circumstances that present a potential conflict of interest							
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Statemen							
Disclosure Stateme	nt						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.							
Dr. Wong reports grants from Agency for Healthcare Research Quality, grants from National Institutes of Health, during the conduct of the study; personal fees from American College of Physicians, personal fees from Cambridge Press, personal fees from Wolters Kluwer, outside the submitted work; .Dr. Wong reports grants from Agency for Healthcare Research and Quality, during the conduct of the study; personal fees from American College of Physicians, personal fees from Cambridge Press, personal fees from Wolters Kluwer, outside the submitted work; .							



### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.